Company Description
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.
The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.
In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis.
Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.
Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1998 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 373 |
| CEO | Helen Torley |
Contact Details
Address: 12390 El Camino Real San Diego, California 92130 United States | |
| Phone | 858 794 8889 |
| Website | halozyme.com |
Stock Details
| Ticker Symbol | HALO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001159036 |
| CUSIP Number | 40637H109 |
| ISIN Number | US40637H1095 |
| Employer ID | 88-0488686 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. | President, Chief Executive Officer and Director |
| Dr. Michael J. LaBarre Ph.D. | Senior Vice President and Chief Technology Officer |
| Mark Snyder Esq. | Senior Vice President and Chief Legal Officer |
| Cortney Caudill M.B.A. | Chief Operations Officer |
| Tram Bui | Head of Investor Relations and Corporate Communications |
| Amy Marinne Fox | Chief Human Resources Officer |
| Gary Grote | Chief Commercial Officer |
| Dr. Christopher Wahl M.B.A., M.D. | Chief Business Officer |
| Dr. Charles P. Theuer M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 17, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 16, 2024 | 144 | Filing |
| Oct 15, 2024 | 144 | Filing |
| Oct 9, 2024 | 144 | Filing |
| Oct 8, 2024 | 144 | Filing |
| Sep 26, 2024 | 144 | Filing |
| Sep 25, 2024 | 144 | Filing |